SCHEMBL122355

SCHEMBL122355

Nc1ncc(Br)cc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118541 0.76
SCHEMBL20589976 0.76 KMT2A (0.44)
SCHEMBL22775974 0.76 HTT (0.44)
SCHEMBL907794 0.75
SCHEMBL29849628 0.75
SCHEMBL17255919 0.75 KMT2A (0.65)
SCHEMBL971307 0.75
SCHEMBL332742 0.75
SCHEMBL120637 0.75
SCHEMBL29818515 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112321496-B Method for synthesizing 2-amino-3-chloro-5-trifluoromethylpyridine 内蒙古佳瑞米精细化工有限公司 2022-03-04 CN claimed
CN-112321496-A Method for synthesizing 2-amino-3-chloro-5-trifluoromethylpyridine 内蒙古佳瑞米精细化工有限公司 2021-02-05 CN claimed
EP-4747249-A1 TREM2 MODULATORS Muna Therapeutics ApS (DK) 2026-05-27 EP disclosed
WO-2026104998-A1 SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2026-05-21 WO disclosed
EP-4731207-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2026-04-29 EP disclosed
EP-4716532-A2 BICYCLIC HETEROARYL COMPOUNDS Quantx Biosciences US, Inc. (US) 2026-04-01 EP disclosed
EP-4688159-A1 PARG INHIBITORY COMPOUNDS FoRx Therapeutics AG (CH) 2026-02-11 EP disclosed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-06-05 US disclosed
WO-2025111409-A1 HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING BIOGEN MA INC. (US) 2025-05-30 WO disclosed
EP-2086966-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SmithKline Beecham Corporation (US) 2009-08-12 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO disclosed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO disclosed
CN-101098869-A 5-heteroaryl thiazoles and their use as p13k inhibitors ASTRAZENECA AB (SE) 2008-01-02 CN disclosed
CN-101061200-A Imidazole derivatives and organic electronic device using the same LG CHEMICAL LTD (KR) 2007-10-24 CN disclosed
EP-1841763-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2007-10-10 EP disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed
US-4033975-A Process for the production of 2-amino-3-hydroxypyridine derivatives CIBA-GEIGY CORPORATION (US) 1977-07-05 US disclosed